Amentoflavone Induces Apoptosis and Inhibits NF-κB-modulated Anti-apoptotic Signaling in Glioblastoma Cells

TSUNG-HSIEN YEN1*, CHIA-LING HSIEH2*, TSU-TE LIU3, CHIH-SHENG HUANG4,5, YEN-CHUNG CHEN6, YAO-CHEN CHUANG7, SONG-SHEI LIN8# and FEI-TING HSU9-12#

1Department of Radiology, Cheng Ching General Hospital, Taichung, Taiwan, R.O.C.; 2The Ph.D. Program for Translational Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan, R.O.C.; 3Division of Gastroenterology, Department of Internal Medicine, 4Department of Surgery, and 6Department of Pathology, National Yang-Ming University Hospital, Yilan, Taiwan, R.O.C.; 5Department of Surgery, School of Medicine, National Yang-Ming University, Taipei, Taiwan, R.O.C.; 7Kiang Wu Nursing College of Macau, Macau SAR, P.R. China 8Department of Medical Imaging and Radiological Sciences, Central-Taiwan University of Science and Technology, Taichung, Taiwan, R.O.C.; 9Department of Radiology, School of Medicine, and 11Research Center of Translational Imaging, College of Medicine, Taipei Medical University, Taipei, Taiwan, R.O.C.; 10Department of Medical Imaging, and 12Translational Laboratory, Department of Medical Research, Taipei Medical University Hospital, Taipei, Taiwan, R.O.C.

Abstract. The goal of the present study was to investigate anticancer effect of amentoflavone on glioblastoma cells in vitro. Our results demonstrated that amentoflavone not only significantly reduced cell viability, nuclear factor-kappa B (NF-κB) activation, and protein expression of cellular Fas-associated protein with death domain-like interleukin 1 beta-converting enzyme inhibitory protein (C-FLIP) and myeloid cell leukemia 1 (MCL1), but significantly triggered cell accumulation at the sub-G1 phase, loss of mitochondrial membrane potential, and expression of active caspase-3 and -8. In order to verify the effect of NF-κB inhibitor on expression of anti-apoptotic proteins, we performed western blotting. We found that the NF-κB inhibitor or amentoflavone markedly diminished protein levels of MCL1 and C-FLIP. Taken all together, our findings show that amentoflavone induces intrinsic and extrinsic apoptosis and inhibits NF-κB-modulated anti-apoptotic signaling in U-87 MG cells in vitro.

Glioblastoma is the most common primary malignancy of the adult central nervous system. The 5-year survival rate for patients with glioblastoma is only approximately 4.5% after diagnosis. Patients with glioblastoma have unsatisfactory response to current standard treatments and median survival less than 15 months (1, 2). Therefore, development of adjuvant anticancer therapy may offer benefits for patients with glioblastoma.

Apoptosis, i.e. programmed cell death, can be initiated by anticancer agents through extrinsic and intrinsic pathways (3). Nuclear factor-kappa B (NF-κB), a transcription factor, modulates the hallmarks of cancer by inducing expression of its target genes. Expression of anti-apoptotic proteins such as cellular Fas-associated protein with death domain-like interleukin 1 beta-converting enzyme inhibitory protein (C-FLIP) and myeloid cell leukemia-1 (MCL1) are linked to NF-κB activation and associated with resistance to apoptosis induced by anticancer agents in glioblastoma cells (4-6).

Amentoflavone, a flavonoid isolated from Selaginella tamariscina, is able to cross the blood–brain barrier and afford neuroprotection against neonatal hypoxic-ischemic brain injury (7). In our previous studies, we demonstrated amentoflavone-induced apoptosis and reduced NF-κB activation in MCF-7 breast cancer cells (8, 9). However, the anticancer effect of...
amentoflavone on glioblastoma cells is ambiguous. The aim of the present study was to investigate the effect of amentoflavone on tumor cell growth and NF-κB-modulated anti-apoptotic mechanism by using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, flow cytometry, western blotting, and NF-κB reporter gene assay in glioblastoma cells in vitro. We also used NF-κB inhibitor (QNZ) to verify the effect of NF-κB inactivation on expression of anti-apoptotic-related proteins.

Materials and Methods

**Drugs.** Amentoflavone was purchased from Sigma-Aldrich (St. Louis, MO, USA). Amentoflavone was dissolved using dimethyl sulfoxide (0.1% DMSO) as 10 mM stock solution. NF-κB inhibitor (QNZ) was purchased from Apexbio Technology LLC (Houston, TX, USA) and prepared as 1 mM stock solution in 0.1% DMSO.

**Cell culture.** Human U-87 MG glioblastoma cells were kindly provided by Professor Ruei-Ming Chen, Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University and used for this study. Cells were cultured in Minimum Essential Medium Eagle’s medium supplemented with 10% fetal bovine serum, 1% penicillin-streptomycin (10,000 U/ml) and 1% sodium pyruvate (100 mM) at 37°C in a humidified incubator with 5% CO₂.

**Detection of the sub-G₁ population.** This is a method used to detect cells in the late stage of apoptosis. Propidium iodide (PI) and RNase were purchased from Biovision (Mountain view, CA, USA) and Thermo Fisher Scientific, respectively. U-87 MG cells (5×10⁵) were seeded into 10 cm diameter dishes and grown overnight. Cells were treated with different concentration of amentoflavone (0-200 μM) for 48 h, and then cell viability was analyzed with MTT assay (11). The absorbance in each well, including the blanks, was measured at 570 nm by Multiskan™ GO Microplate Spectrophotometer (Thermo Fisher Scientific, Rockford, IL, USA).

**Detection of mitochondrial membrane potential (Ψₘ).** The signal intensity of each well was corrected for cell viability which was analyzed using MTT assay as described previously (12).

**Statistical analysis.** All statistical analyses were performed using SigmaPlot 10.0 (Systat Software Inc., San Jose, CA, USA). Parametric data are shown as the mean±standard deviation. To compare values between two groups, Student’s t-test was performed. Differences with a p-value less than 0.05 was considered statistically significant.

**Results**

Amentoflavone induced cytotoxicity towards U-87 MG glioblastoma cells. We used MTT assay to evaluate effect of amentoflavone on cell viability in U-87 MG cells.
indicates that amentoflavone treatment (50-200 μM) significantly inhibited the viability of U-87 MG cells by 23-71% at 48 h as compared to controls. The half-maximal inhibitory concentration (IC₅₀) of amentoflavone was 100 μM under the 48 h treatment schedule.

**Amentoflavone-induced apoptosis is dependent on intrinsic and extrinsic apoptotic signaling pathways in U-87 MG glioblastoma cells.** Amentoflavone-induced apoptotic signaling was analyzed using flow cytometric apoptosis assays. Figure 2A and B show that amentoflavone significantly induced the accumulation of cells in the sub-G₁ population and increased the level of active caspase-3 by 14-52% and 24-42%, respectively, at 48 h as compared to controls. We also found amentoflavone significantly triggered the loss of Ψₘ and the expression of active caspase-8 by 23-53% and 25-50%, respectively, at 48 h as compared to controls (Figure 2C and D).

**Blockage of NF-κB activation reduces expression of anti-apoptotic proteins MCL1 and C-FLIP in U-87 MG glioblastoma cells.** We used QNZ, a specific NF-κB inhibitor, to verify the effect of NF-κB inactivation on expression of anti-apoptotic proteins MCL1 and C-FLIP in U-87 MG cells. NF-κB reporter gene assay was performed to verify the effect of QNZ on NF-κB activation. Relative NF-κB activity was corrected with cell viability. Figure 3A indicates that amentoflavone significantly suppressed NF-κB activation in a dose-dependent manner by 23-71% at 48 h as compared to the control. We also found 0.3 μM QNZ significantly reduced protein levels of MCL1 and C-FLIP by 87% and 79%, respectively, at 48 h as compared to controls (Figure 3B).

**Amentoflavone diminishes protein expression of MCL1 and C-FLIP through suppression of NF-κB activation in U-87 MG glioblastoma cells.** Figure 4A shows amentoflavone significantly reduced NF-κB activation in a dose-dependent manner by 25-87% at 48 h as compared to the control. Amentoflavone significantly reduced protein expression of MCL1 and C-FLIP by 50-80% and 38-57%, respectively, at 48 h as compared to controls (Figure 4B).

**Discussion**

Amentoflavone has been reported to trigger apoptosis and reduce NF-κB activation in breast cancer and melanoma cells (8, 9, 14). The effects of amentoflavone on glioblastoma cells has not been elucidated. Therefore, we evaluated the effect of amentoflavone on tumor cell growth and NF-κB-modulated anti-apoptotic signaling in U-87 MG cells *in vitro*.

Many cytotoxic agents inhibit growth of glioblastoma cells by inducing apoptosis (15). Apoptotic signaling pathways are divided into intrinsic (mitochondria) and extrinsic (death receptors) pathways (16). Temozolomide (TMZ), an oral O6-methylating agent used for treatment of glioblastoma, has been shown to trigger intrinsic and extrinsic apoptosis by inducing DNA lesion in O6-methylguanine. Active caspase-8 is key mediator of the extrinsic apoptotic signaling pathway (17). DNA fragmentation initiated by active caspase-3 can be triggered via intrinsic and extrinsic apoptotic signaling pathways. High expression of cleaved caspase-8 and active caspase-3 are positive prognostic indicators for patients with glioma (1, 18). Figure 2B and D indicate amentoflavone significantly induced expression of active caspase-3 and -8, while Figure 2C shows amentoflavone significantly induced loss of Ψₘ, all associated with apoptosis.

Constitutive activation of NF-κB was observed in glioma and correlated with glioma grade (19). High expression of NF-κB contributes tumor progression and modulates acquired resistance to treatment in glioblastoma (20). TMZ not only induces apoptosis but also triggers NF-κB activity in glioblastoma cells. Therapeutic efficacy of TMZ is limited because of overexpression of NF-κB-modulated anti-apoptotic proteins; inhibition of NF-κB activation sensitizes glioblastoma cells to TMZ (21, 22). Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a potential anticancer agent because it induces apoptosis leading to tumor growth inhibition in cancer (23). MCL1 and C-FLIP are disruptors of intrinsic and extrinsic apoptotic pathways, respectively. Protein expression of MCL1 and C-FLIP are modulated by NF-κB activation in cancer (12). Han *et al.* showed that silencing NF-κB reduced C-FLIP expression and enhanced TRAIL-induced apoptosis in glioblastoma cells (24). Murphy *et al.* also demonstrated that silencing MCL1 increased sensitivity to
Figure 2. U-87 MG cells were treated with 0, 50, 100 μM amentoflavone for 48 h and prepared for cell cycle and caspase-3 flow cytometry (A, B), or analyzed for mitochondrial membrane potential and caspase-8 (C, D). **Significantly different at p<0.01 vs. 0 μM.
TRAIL in glioblastoma cells (6). We confirmed such effects by finding that NF-κB inhibitor reduced NF-κB activation and protein expression of MCL1 and C-FLIP in U-87 MG cells (Figure 3). We also found amentoflavone, as an inhibitor of NF-κB signaling, reduced expression of NF-κB-modulated anti-apoptotic proteins MCL1 and C-FLIP (Figure 4A and B).

**Conclusion**

In conclusion, the present study demonstrated that amentoflavone not only induced intrinsic and extrinsic apoptosis, but also reduced NF-κB-modulated anti-apoptosis signaling in glioblastoma cells in vitro. We suggest amentoflavone as a potential adjuvant which may provide benefit for treatment of patients with glioblastoma.

**Financial & Competing Interests Disclosure**

The Authors declare no competing financial interests.

**Acknowledgements**

This study was supported by Taipei Medical University/Taipei Medical University Hospital (Grant no. 105TMU-TMUH-23, TMU105-AE1-B49 and 106TMU-TMUH-27). This study was also supported by Grants RD2017-023, CTU105-CCGH-001, and CTU105-P-16 from...
Figure 4. A: U-87 MG cells (2×10⁵) were seeded in 96-well plates and treated with 0-200 μM amentoflavone in 0.1% dimethylsulfoxide (DMSO) for 48 h. Nuclear factor-κB (NF-κB) activation was evaluated by reporter gene assay. Relative NF-κB activity of each group was normalized with viability and calculated through dividing by the value for the control group treated with 0.1% DMSO. B: Cells were treated with 0, 50, 100 μM amentoflavone for 48h and harvested for western blotting assay. The quantification of protein expression of myeloid cell leukemia 1 (MCL1) and cellular Fas-associated protein with death domain-like interleukin 1 beta-converting enzyme inhibitory protein (C-FLIP) was measured by Image J. **Significantly different at p<0.01 vs. 0 μM.

References


Received November 23, 2017
Revised December 14, 2017
Accepted December 18, 2017